Table 1.
Patient and tumour characteristics of the non‐small cell lung cancer cohort. PY = pack years
| Frequencies (n = 635) | |
|---|---|
| Gender | |
| Male | 363 (57.2%) |
| Female | 272 (42.8%) |
| Median age at surgery (years, range) | 64 (30–84) |
| Neo‐adjuvant therapy | |
| Chemotherapy | 25 (3.9%) |
| Concurrent chemo radiotherapy | 14 (2.2%) |
| Sequential chemo radiotherapy | 3 (0.5%) |
| Erlotinib [52] | 31 (4.9%) |
| Radiotherapy | 3 (0.5%) |
| No adjuvant therapy | 532 (84.8%) |
| Smoking | |
| Light smokers <10 PY | 48 (7.6%) |
| Heavy smokers ≥10 PY | 497 (78.3%) |
| Unknown | 90 (14.2%) |
| Packyears (median, range) | 38 (0–150) |
| Histology | |
| Adenocarcinoma | 329 (51.8%) |
| Squamous cell carcinoma | 278 (43.8%) |
| Large cell carcinoma | 28 (4.4%) |
| Tumour stage at resection | |
| Tis | 1 (0.2%) |
| Stage I | 352 (55.4%) |
| Stage II | 181 (28.5%) |
| Stage III | 82 (12.9%) |
| Stage IV | 17 (2.7%) |
| Unknown | 2 (0.3%) |
| Median overall survival (months, range) | 49.0 (0–289) |